Characterization of crosslinked hard gelatin capsules for a structural assembly of elementary osmotic pump delivery system

Journal of Pharmaceutical Investigation - Tập 49 - Trang 655-665 - 2019
Chaowalit Monton1, Poj Kulvanich1
1College of Pharmacy, Rangsit University, Pathum Thani, Thailand

Tóm tắt

The objective of this study was to characterize the crosslinked hard gelatin capsules (HGCs) for use as a structural assembly of elementary osmotic pumps (EOP). HGCs were crosslinked in formaldehyde vapor for 6, 12, and 24 h. Weight loss after immersing in various mediums, water soluble protein fraction, loss on drying, and formaldehyde residue were investigated. Fourier transform infrared (FTIR) spectra were used to detect the crosslinking formation. The EOP capsules were prepared for delivery of diltiazem hydrochloride (DIL HCl) and ambroxol hydrochloride (AMB HCl), which are freely and sparingly water soluble drugs, respectively. Physicochemical stability of storage crosslinked HGC shells was investigated. All crosslinked HGC shells were water insoluble. FTIR spectra exhibited intermediate lysine methylol and arginine methylol peaks. Storage time increased, moisture content increased and formaldehyde residue decreased. The developing EOP capsules were more appropriate for delivery of high water soluble rather than low water soluble drug. EOP capsule contained 100 mg DIL HCl using HGCs crosslinked for 12 h provided release profiles for 12 h with a lag time of 2.6–3.1 h. It was also found that DIL HCl EOP capsules prepared using crosslinked HGC shells stored for 90 days maintained the similar drug release profiles. AMB HCl EOP capsules exhibited low drug release. In summary, the crosslinked HGCs were applicable as a structural assembly of the osmotic controlled drug delivery system.

Tài liệu tham khảo

Augsburger LL (2009) Hard- and soft-shell capsules. In: Florence AT, Siepmann J (eds) Modern pharmaceutics-basic principles and systems, 5th edn. CRC Press, Florida, p 511 Chauhan CS, Ranawat MS, Choudhury PK (2007) Fabrication and evaluation of asymmetric membrane osmotic pump. Ind J Pharm Sci 69:748–752 Chiwele I, Jones BE, Podczeck F (2000) The shell dissolution of various empty hard capsules. Chem Pharm Bull (Tokyo) 48:951–956 Colorcon (2012) Polyox™ water soluble resins. https://www.colorcon.com/products-formulation/all-products/download/782/2124/34?method=view. Accessed 2 Apr 2015 Conley R, Gupta SK, Sathyan G (2006) Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr Med Res Opin 22:1879–1892. https://doi.org/10.1185/030079906x132613 Council of Europe (2005) Free formaldehyde. http://lib.njutcm.edu.cn/yaodian/ep/EP5.0/02_methods_of_analysis/2.4.__limit_tests/2.4.18.%20Free%20formaldehyde.pdf. Accessed 9 June 2015 Davar N, Barcley B, Gupta S (2008) Osmotic systems. In: Augsburger LL, Hoag SW (eds) Pharmaceutical dosage forms: tablets, 3rd edn. Informa Healthcare, New York, pp 493–507 Derakhshandeh K, Berenji MG (2014) Development and optimization of buspirone oral osmotic pump tablet. Res Pharm Sci 9:233–241 Gobade N, Koland M, Harish K (2012) Asymmetric membrane osmotic capsules for terbutaline sulphate. Ind J Pharm Sci 74:69–72. https://doi.org/10.4103/0250-474x.102546 Guan J, Zhou L, Pan Y, Han H, Xu H, Pan W (2010) A novel gastro-retentive osmotic pump capsule using asymmetric membrane technology: in vitro and in vivo evaluation. Pharm Res 27:105–114. https://doi.org/10.1007/s11095-009-9984-1 Higuchi T, Leeper HM (1976) Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient. US patent no.3995631 ICH Expert Working Group (2015) Addendum to ICH M7: assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk: Application of the principles of the ICH M7 guideline to calculation of compound-specific acceptable intakes M7(R1). Accessed 10 Oct 2018 Liu L, Ku J, Khang G, Lee B, Rhee JM, Lee HB (2000) Nifedipine controlled delivery by sandwiched osmotic tablet system. J Control Release 68:145–156. https://doi.org/10.1016/S0168-3659(00)00243-1 Liu D, Yu S, Zhu Z, Lyu C, Bai C, Ge H, Yang X, Pan W (2014) Controlled delivery of carvedilol nanosuspension from osmotic pump capsule: in vitro and in vivo evaluation. Int J Pharm 475:496–503. https://doi.org/10.1016/j.ijpharm.2014.09.008 Salsa T, Pina ME, Teixeira-Dias JJC (1996) Crosslinking of gelatin in the reaction with formaldehyde: an FT-IR spectroscopic study. Appl Spectrosc 50:1314–1318. https://doi.org/10.1366/0003702963904881 Santus G, Baker RW (1995) Osmotic drug delivery: a review of the patent literature. J Control Release 35:1–21. https://doi.org/10.1016/0168-3659(95)00013-X Singh S, Rao KVR, Venugopal K, Manikandan R (2002) Alteration in dissolution characteristics of gelatin-containing formulations: a review of the problem, test methods, and solutions. Pharm Technol 26:36–58 Sonkar A, Kumar A, Pathak K (2016) Cellulose acetate 398–10 asymmetric membrane capsules for osmotically regulated delivery of acyclovir. J Pharm 2016:12. https://doi.org/10.1155/2016/8471520 Tengroth C, Gasslander U, Andersson FO, Jacobsson SP (2005) Cross-linking of gelatin capsules with formaldehyde and other aldehydes: an FTIR spectroscopy study. Pharm Dev Technol 10:405–412. https://doi.org/10.1081/pdt-65693 Theeuwes F (1975) Elementary osmotic pump. J Pharm Sci 64:1987–1991. https://doi.org/10.1002/jps.2600641218 US Environmental Protection Agency (2000) Formaldehyde. http://www3.epa.gov/airtoxics/hlthef/formalde.html. Accessed 7 Jan 2016 US Environmental Protection Agency (2001) Formaldehyde. http://www.euro.who.int/__data/assets/pdf_file/0014/123062/AQG2ndEd_5_8Formaldehyde.pdf. Accessed 23 Jun 2015 Verma RK, Mishra B, Garg S (2000) Osmotically controlled oral drug delivery. Drug Dev Ind Pharm 26:695–708. https://doi.org/10.1081/ddc-100101287 Walker JM (2002) The bicinchoninic acid (BCA) assay for protein quantitation. In: Walker JM (ed) The protein protocols handbook. Humana Press, New Jersey, pp 11–14 Waterman KC, Goeken GS, Konagurthu S, Likar MD, MacDonald BC, Mahajan N, Swaminathan V (2011) Osmotic capsules: a universal oral, controlled-release drug delivery dosage form. J Control Release 152:264–269. https://doi.org/10.1016/j.jconrel.2011.02.001 Wichianprasit N, Kulvanich P (2009) Osmotically controlled drug delivery system using a crosslinked and non-crosslinked hard gelatin capsule. Abstracts, Asian Federation of Pharmaceutical Sciences Conference, Fukuoka, Japan. p 193 Wong PSL, Gupta SK, Stewart BE (2003) Osmotically controlled tablets. In: Rathbone MJ, Hadgraft J, Roberts MS (eds) Modified-release drug delivery technology, 2nd edn. Informa Healthcare, New York, pp 101–114 Yang Y, Zhao Z, Wang Y, Yang L, Liu D, Yang X, Pan W (2016) A novel asymmetric membrane osmotic pump capsule with in situ formed delivery orifices for controlled release of gliclazide solid dispersion system. Int J Pharm 506:340–350. https://doi.org/10.1016/j.ijpharm.2016.04.061